VCNX: Bathi resik saben saham (EPS TTM) Vaccinex, Inc

Vaccinex, Inc. (VCNX) possesses robust R&D potential driven by its pepinemab platform for cancer treatment. The TTM net income per share reflects profit dynamics, where a metric value of 7.44 serves as an indicator of resilience. US-based operations are shielded from trade conflicts, while production outsourcing allows the team to maintain flexibility without incurring unnecessary costs.

VCNX Bathi resik saben saham sajrone 12 wulan pungkasan Vaccinex, Inc. (04.07.2022 - 28.12.2024)

Ringkesan rincian data analitis Vaccinex Inc (VCNX)

- rega saham lan prakiraan rega para ahli:

Kutipan saham Vaccinex|VCNX - Konsensus nilai wajar

- informasi kapitalisasi pasar:

Kapitalisasi pasar Vaccinex|VCNX - Rega Tumbas Perusahaan

- rincian valuasi buku bisnis:

Aset Bersih saben Siji Saham Vaccinex|VCNX - Aset Bersih Perusahaan|Rasio Nilai Pasar marang Nilai Buku vaccinex.com|VCNX - Gunggung Aset Perusahaan

- indikator beban kredit lan likuiditas emiten:

- data bathi lan kelipatan valuasi:

VCNX - Bathi sawise mbayar pajeg|Proyeksi bathi mangsa ngarep Vaccinex, Inc.|VCNX - Nilai perusahaan marang bathi resik|Pangali Forward P/E vaccinex.com|VCNX - Rega marang bathi kanthi panyesuaian wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Vaccinex Inc|VCNX - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) Vaccinex|VCNX - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan vaccinex.com|VCNX - Dinamika bathi saben saham ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Vaccinex, Inc.

- rincian pendapatan lan dodolan:

VCNX - Total pendapatan perusahaan|Volume dodolan mangsa ngarep perusahaan Vaccinex|VCNX - Rasio rega marang pendapatan|Multiplikator Forward P/S Vaccinex Inc.

Pambiji fundamental:VCNX - Vaccinex Inc

Net income per share for Vaccinex, Inc. (VCNX) is calculated as the ratio of total annual income to the total number of securities. This indicator filters out market noise, demonstrating real profitability trends without the influence of one-off transactions. The current value of 7.44 reflects financial pressure caused by costs associated with cancer therapy clinical trials. Risks regarding the prolongation of contracts with pharma behemoths make the 12-month rolling EPS a critical marker of stability. Analyzing this trend helps avoid investing in an asset with depleting capital.

Pesaing utama